AbbVie and REGENXBIO Announce Updates on the ABBV-RGX-314 Clinical Program
Pivotal data evaluating the safety and efficacy of the subretinal delivery of ABBV-RGX-314 in patients with wet age-related macular degeneration (wet AMD) are expected in 2026AbbVie and REGENXBIO will plan